So Allovectin-7 something that we’ve been working for very long time, we’re pretty excited the pivotal data from this program will be coming out by the end of this year. It’s a systemic immunotherapy, but the beauty of it, it’s given locally. So the fact that it’s given locally, but works systemically does not have the side effects of traditional systemic drugs.
We have treated about 900 patients in variety of cancer applications, its well tolerated. Let me give an example of how it’s given, it’s given in the outpatient setting one injection per week into the lesion and you repeat every week for six weeks in a row followed by two week of observation period.
So one cycle of treatment is about eight weeks, in eight weeks you get six injections. Most patients start showing benefit of the drug after about two cycles of treatment, which is 16 weeks or four months. So, the key thing that you need to understand as you walk through my presentation that in immunotherapy the patients need to live long enough to benefit from immunotherapy.
It has a unique mechanism of action, I’m not going to spend a lot of time talking about it, you can go to our website and look at it. But, I think the most important thing it has potential synergies with currently approved new therapies for melanoma, it has an orphan drug status or fast-track status. With all the U.S. and EU commercial rights and we have an SP or a Special Protocol assessment with the agency.Our people ask, what’s the melanoma market now that the new two drugs have been approved. There is plenty of room for melanoma. Melanoma is not been cured, the two drugs have benefits, but they have their own toxicity. These kind of patients we’re treating in our Phase 3 trial will represent about third of the vulvar melanoma patients. The current drugs have been priced at $60,000 to $120,000 per therapy, so plenty of room a huge commercial opportunity for a company for our size.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV